[New treatments for heart failure?].
Treatment of chronic heart failure still needs to be improved. Blockade of ET-1 and TNF-alpha, as well as the combined inhibition of ACE and NE have demonstrated limited benefits, thus other strategies continue being evaluated. This article reviews current concepts regarding the blockade of arginine vasopressin receptors (AVP) and the selective inhibition of matrix metalloproteinases (MMPs). Results with AVP blockade in humans have been encouraging, whereas inhibitors of MMPs continue under preclinical experimental phases and are controversial.
Olvera Cruz
Sergio
S
Clínica de Insuficiencia Cardíaca, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D.F.
D065092:Antidiuretic Hormone Receptor Antagonists; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D045726:Metalloproteases / Q000037:antagonists & inhibitors
D065092:Antidiuretic Hormone Receptor Antagonists; D045726:Metalloproteases
Nuevas terapéuticas para la insuficiencia cardíaca?